Skip to main content

Kimberly-Clark bets $40 billion for Kenvue despite Tylenol controversy

Tylenol,Acquisitions

From the Center

Kimberly-Clark is laying down $40 billion to buy Kenvue in a massive deal that has puzzled some investors as the Tylenol maker struggles with weak sales, lawsuits and White House attacks linking its painkiller to autism.

AllSides Picks

More News about Healthcare

News from the Left

News from the Center

News from the Right